Skip to main content
. 2014 Sep;5(9-10):303–305. doi: 10.18632/genesandcancer.34

Figure 2. TMEPAI expression levels are prognostic for relapse-free survival in HER2+ breast cancer.

Figure 2

HER2-expressing intrinsic subtype breast cancer patients, divided into three groups based upon TMEPAI (PMEPA1) transcript levels (grey trace, low expression, n=40 patients; red trace, medium expression, n=42 patients; blue trace, high expression, n=40 patients) showed significant differences (p=0.00095) in relapse-free survival (RFS). Meta-analysis performed using the GOBO server (http://co.bmc.lu.se/gobo/gsa.pl).